Clinical Trials

This portal provides clinical trials information solely for education and awareness purposes. Information includes: what clinical trials are, entering a clinical trial, and why clinical trial participation is important for African Americans. Through ClinicalTrials.gov information is assembled for more that 2,000 prostate cancer clinical trials/research studies. Certain clinical trials are highlighted for organizations who support PHEN's education and awareness initiatives.

PHEN does not provide clinical trials medical advice, or recommendations to patients. Patients should consult their medical doctor for advice and recommendations about specific clinical trials.


PHEN Clinical Trials Rally

An overview about prostate cancer clinical trials and African American men; The PHEN Clinical Trials Rally objectives and information on how the linical Trials Rally works.

Information

What Are Clinical Trials?

A description of what clinical trials are, outlining their purpose and who is involved. Information also includes videos.

Information

Entering A Clinical Trial, Is It Right For You?

A Dana-Farber video to assist patients in understanding and making choices about clinical trials.

Information
Levi Garraway, MD, PhD

Precision Medicine Is Decoding the Mysteries of Cancer
Levi Garraway, MD, PhD
Dr. Garraway speaks on decoding the mysteries of cancer and developing new drugs and treatments to disarm this deadly disease.

Information
Isaac Powell, MD, Professor, Dept. of Urology, Wayne State Univ., Detroit, MI

Genetic and Biologic Differences in Prostate Cancer for African American and European American Men
Isaac Powell, MD, Professor, Dept. of Urology, Wayne State Univ., Detroit, MI
Dr. Powell presents on prostate cancer genetic and biologic differences and the need for more research studies for African American men.

Information
Dr.'s Chiledum Ahaghotu, Robert Tyler and Oliver Sartor

African American Participation in Oncology Clinical Trials—Focus on Prostate Cancer:
Dr.'s Chiledum Ahaghotu, Robert Tyler and Oliver Sartor
"In addition to improving access to novel therapies, clinical trial participation is essential to adequately establish the risks and benefits of treatments in African American populations."

Information

Prostate Cancer Clinical Trials

Information providing the purpose, description, eligibility criteria and status for more than 1700 prostate cancer clinical trials/studies in the United States.

Information

PRESIDE

A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone

Information

EMBARK

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.

Information

PROSPER

A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer

Information

ENACT

The primary purpose of this study is to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.

Information

ERA 223

To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated with an X-ray machine. NOTE:THIS TRIAL IS NOW CLOSED TO ENROLLMENT.

Information

ARAMIS

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.

Information

SPARTAN

Prostate Health Education Network The purpose of this study is to evaluate the efficacy and safety of ARN-509 in adult men with high-risk non-metastatic castration-resistant prostate cancer.

Information

ATLAS

The purpose of this study is to evaluate the efficacy and safety of an investigational medication in adult men with high risk, localized or locally advanced prostate cancer.

Information

TITAN

The purpose of this study is to evaluate the efficacy and safety of an oral investigational medication in adult men with metastatic, hormone-resistant prostate cancer.

Information

Abiraterone - Race in Metastatic Castrate-resistant Prostate Cancer

The primary goal is to prospectively estimate the median radiographic PFS (progression free survival) of African American and Caucasian men with mCRPC (metastatic castrate resistant prostate cancer) to abiraterone acetate and prednisone.

Information
Molecular Mechanisms Underlying Prostate Cancer Disparities


Molecular Mechanisms Underlying Prostate Cancer Disparities
The purpose of this study is to further elucidate the molecular mechanisms underlying prostate cancer disparities. In previous work the investigators have identified a set of differentially deregulated genes in African American versus Caucasian American prostate cancer.

Information
Validation of Decipher Test in African American Men With Prostate Cancer

VANDAAM
Validation of Decipher Test in African American Men With Prostate Cancer
The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same accuracy in African-American men (AAM) as in non-African-American men (NAAM).

Information

ProstAtak™

This study will evaluate the effectiveness of ProstAtak™ immunotherapy to reduce the recurrence of intermediate-high risk localized prostate cancer when used in combination with radiation therapy.

Information

Cyberknife

Prostate cancer clinical trials for the CyberKnife® Robotic Radiosurgery System - a non-invasive alternative to surgery.

Information
PROSPECT

BN ImmunoTherapeutics
PROSPECT
PROSTVAC® is a therapeutic vaccine candidate in Phase 3 clinical development that has the potential to significantly extend the lives of men with advanced prostate cancer.

Information

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown.

Information




PHEN,Inc. © 2016 All rights reserved